Pharmaceutical industry and related studies indicate the U.K.'s National Institute for Clinical Excellence, which recommends to the National Health Service which drugs to cover, has little impact on the introduction of new treatments. If the NICE recommendations had been adopted, according to studies by Roche, NICE and the Association of British Pharmaceutical Industry, they would have added millions to NHS drug coverage costs.

Related Summaries